Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors.
Sarah P. Blagden(Churchill Hospital), Mark R. Middleton(University of Oxford), M. Dar, A Seebaran(Churchill Hospital), Miranda Payne(Churchill Hospital), Andrew Protheroe(University of Oxford), Jeffrey P. Hodge(Research Triangle Park Foundation), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Steven J. Kathman(Research Triangle Park Foundation), R. Molife(Royal Marsden NHS Foundation Trust), Alison Reid(Royal Marsden NHS Foundation Trust), Carolyn J. Bowen, Dallas Williams
Clinical Cancer Research
December 15, 2005
Cited by 1
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k